XIDALI® Tadalafil Tablets Officially Launched! 36-Hour Long-Acting

Therapy for ED Recently, XIDALI® Tadalafil Tablets (Approval No. H20255227) produced by Yangling Jitai Pharmaceutical Co., Ltd. has been approved and launched, providing a longer-acting, more convenient and safer solution for the treatment of male erectile dysfunction (ED).

With the philosophy of Scientifically Improve Men’s Health, Rebuild Life Confidence, XIDALI® is a yellow, heart-shaped, film-coated tablet with a strength of 20mg. As a long-acting PDE5 inhibitor, it has a half-life of 17.5 hours and lasts up to 36 hours, allowing flexible dosing without strict timing.The absorption is not affected by high-fat meals, with onset in 30 minutes to 1 hour. Stable plasma concentration can be achieved with regular use. It shows excellent safety with low cross-inhibition on enzymes related to retina and testis, and fewer side effects.

Clinical data show that after 8 weeks of treatment, the improvement rate of erectile function is 82%, and 76% in severe ED patients. Sexual satisfaction increases by 45%, effectively relieving anxiety, enhancing confidence and improving overall quality of life.

Dosage: The recommended dose for adult men is 20mg, taken 30 minutes to 1 hour before sexual activity, maximum once daily.Concomitant use with nitrates is contraindicated. Dose adjustment is required for patients with hepatic or renal impairment and the elderly under medical advice. Not for use under 18 years of age.

China’s ED market continues to grow with a younger patient population. XIDALI® offers distinct advantages in long duration, convenience, safety and cost-effectiveness, becoming a reliable new choice for clinics and patients.

Yangling Jitai Pharmaceutical focuses on men’s health, protects public health with innovative medicines, and helps more men regain confidence and return to a high-quality life.

Note: This product is a prescription drug. Please purchase and use under the guidance of a doctor or pharmacist.